{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:35:28Z","timestamp":1790998528271,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"am","delay-in-days":278,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21AR082609"],"award-info":[{"award-number":["R21AR082609"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AR075042"],"award-info":[{"award-number":["P30 AR075042"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R21AR077292"],"award-info":[{"award-number":["R21AR077292"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003227","name":"Osteogenesis Imperfecta Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bone.2025.117641","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:57:47Z","timestamp":1757573867000},"page":"117641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Enhancing Wnt signaling lowers fracture incidence in a severe mouse model of Osteogenesis Imperfecta"],"prefix":"10.1016","volume":"202","author":[{"given":"Giulia","family":"Montagna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Baacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Warman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2025.117641_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10028","key":"10.1016\/j.bone.2025.117641_bb0010","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bone.2025.117641_bb0015","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"10","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2025.117641_bb0020","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2018.05.021","article-title":"A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood","volume":"113","author":"Feehan","year":"2018","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2025.117641_bb0025","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12891-018-2252-y","article-title":"Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta","volume":"19","author":"Garganta","year":"2018","journal-title":"BMC Musculoskelet. Disord."},{"issue":"7","key":"10.1016\/j.bone.2025.117641_bb0030","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jbmr.2805","article-title":"Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating?","volume":"31","author":"Vasanwala","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2025.117641_bb0035","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/os.12611","article-title":"Oral bisphosphonate therapy for osteogenesis imperfecta: a systematic review and meta-analysis of six randomized placebo-controlled trials","volume":"12","author":"Ying","year":"2020","journal-title":"Orthop. Surg."},{"issue":"2","key":"10.1016\/j.bone.2025.117641_bb0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1359\/jbmr.090720","article-title":"Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model","volume":"25","author":"Daley","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2025.117641_bb0045","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bone.2025.117641_bb0050","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin antibody treatment improves the bone phenotype of Crtap\u2212\/\u2212 mice, a model of recessive Osteogenesis Imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117641_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116378","article-title":"Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta","volume":"159","author":"Lee","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.bone.2025.117641_bb0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bone.2016.09.013","article-title":"Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl\/+ osteogenesis imperfecta model","volume":"93","author":"Perosky","year":"2016","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2025.117641_bb0065","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.081238","article-title":"Alendronate treatment of the Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation","volume":"24","author":"Uveges","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2025.117641_bb0070","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00223-019-00655-5","article-title":"Sclerostin-antibody treatment decreases fracture rates in axial skeleton and improves the skeletal phenotype in growing oim\/oim mice","volume":"106","author":"Cardinal","year":"2020","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2025.117641_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","article-title":"Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta","volume":"124","author":"Cardinal","year":"2019","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2025.117641_bb0080","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/jbmr.2177","article-title":"First mouse model for combined osteogenesis imperfecta and ehlers-danlos syndrome","volume":"29","author":"Chen","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2025.117641_bb0085","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0092-8674(81)90343-3","article-title":"Chromosomal position and activation of retroviral genomes inserted into the germ line of mice","volume":"24","author":"Jaenisch","year":"1981","journal-title":"Cell"},{"key":"10.1016\/j.bone.2025.117641_bb0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/9780470942390.mo110217","article-title":"Health evaluation of experimental laboratory mice","volume":"2","author":"Burkholder","year":"2012","journal-title":"Curr. Protoc. Mouse Biol."},{"issue":"6","key":"10.1016\/j.bone.2025.117641_bb0095","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nm.2388","article-title":"Lrp5 functions in bone to regulate bone mass","volume":"17","author":"Cui","year":"2011","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.bone.2025.117641_bb0100","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2025.117641_bb0105","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.bone.2016.06.005","article-title":"Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+\/mov13) mouse model of type I Osteogenesis Imperfecta","volume":"90","author":"Jacobsen","year":"2016","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2025.117641_bb0110","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/jbmr.2461","article-title":"The anti-osteoanabolic function of sclerostin is blunted in mice carrying a high bone mass mutation of Lrp5","volume":"30","author":"Yorgan","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2025.117641_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0040007","article-title":"ER stress-mediated apoptosis in a new mouse model of Osteogenesis imperfecta","volume":"4","author":"Lisse","year":"2008","journal-title":"PLoS Genet."},{"issue":"20","key":"10.1016\/j.bone.2025.117641_bb0120","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2025.117641_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","author":"Little","year":"2002","journal-title":"Am. J. Hum. Genet."},{"issue":"11","key":"10.1016\/j.bone.2025.117641_bb0130","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","author":"Ellies","year":"2006","journal-title":"J. Bone Miner. Res."},{"issue":"50","key":"10.1016\/j.bone.2025.117641_bb0135","doi-asserted-by":"crossref","first-page":"38276","DOI":"10.1074\/jbc.M609509200","article-title":"LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST","volume":"281","author":"Semenov","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bone.2025.117641_bb0140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2144\/00291bm09","article-title":"Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT)","volume":"29","author":"Truett","year":"2000","journal-title":"Biotechniques"},{"issue":"10","key":"10.1016\/j.bone.2025.117641_bb0145","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1523\/JNEUROSCI.2274-13.2014","article-title":"Decreased anxiety-like behavior and Galphaq\/11-dependent responses in the amygdala of mice lacking TRPC4 channels","volume":"34","author":"Riccio","year":"2014","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.bone.2025.117641_bb0150","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.bone.2025.117641_bb0155","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1086\/368277","article-title":"Six novel missense mutations in the LDL Receptor-Related Protein 5 (LRP5) gene in different conditions with an increased bone density","volume":"72","author":"Van Wesenbeeck","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bone.2025.117641_bb0160","unstructured":"F. Cosman, D.B. Crittenden, J.D. Adachi, N. Binkley, E. Czerwinski, S. Ferrari, L.C. Hofbauer, E. Lau, E.M. Lewiecki, A. Miyauchi, C.A.F. Zerbini, C.E. Milmont, L. Chen, J. Maddox, P.D. Meisner, C. Libanati, A. Grauer, Romosozumab Treatment in Postmenopausal Women with Osteoporosis, N. Eng. J. Med., 10.1056\/NEJMoa1607948."},{"issue":"1","key":"10.1016\/j.bone.2025.117641_bb0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1258\/la.2008.007156","article-title":"Automated analysis of postoperative behaviour: assessment of HomeCageScan as a novel method to rapidly identify pain and analgesic effects in mice","volume":"43","author":"Roughan","year":"2009","journal-title":"Lab. Anim."},{"issue":"40","key":"10.1016\/j.bone.2025.117641_bb0170","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030256","article-title":"Chronic pain in adults with osteogenesis imperfecta and its relationship to appraisal, coping, and quality of life: A cross-sectional study","volume":"101","author":"Munoz Cortes","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.bone.2025.117641_bb0175","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/AJP.0000000000000395","article-title":"Pain experiences of children and adolescents with osteogenesis imperfecta: an integrative review","volume":"33","author":"Nghiem","year":"2017","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.bone.2025.117641_bb0180","first-page":"175","article-title":"Irisin reduces bone fracture by facilitating osteogenesis and antagonizing TGF-\u03b2\/Smad signaling in a growing mouse model of osteogenesis imperfecta","volume":"38","author":"Sun","year":"2023","journal-title":"J. Orthop. Transl."},{"issue":"4","key":"10.1016\/j.bone.2025.117641_bb0185","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/jbmr.4501","article-title":"4-PBA treatment improves bone phenotypes in the Aga2 mouse model of osteogenesis imperfecta","volume":"37","author":"Duran","year":"2022","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2025.117641_bb0190","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1038\/s41598-023-32221-3","article-title":"Effect of sclerostin inactivation in a mouse model of severe dominant osteogenesis imperfecta","volume":"13","author":"Marulanda","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2025.117641_bb0195","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.bone.2016.04.011","article-title":"Bone mineral properties in growing Col1a2(+\/G610C) mice, an animal model of osteogenesis imperfecta","volume":"87","author":"Masci","year":"2016","journal-title":"Bone"},{"issue":"20","key":"10.1016\/j.bone.2025.117641_bb0200","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225002534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328225002534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:28:42Z","timestamp":1780558122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328225002534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":40,"alternative-id":["S8756328225002534"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2025.117641","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2025.05.27.656429","asserted-by":"object"}]},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing Wnt signaling lowers fracture incidence in a severe mouse model of Osteogenesis Imperfecta","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2025.117641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117641"}}